A story in Forbes says medical professionals and industry analysts are both keeping a close eye on Johnson & Johnson’s Invokana, newly approved by the U.S. Food and Drug Administration. It’s the first to be approved among a new class of medications that treat type 2 diabetes by reducing blood sugar, rather than affecting the supply or use of insulin.
While the drug has the potential to be a blockbuster for ...
continue reading...
Researchers at Brigham and Women’s Hospital in Boston have released a study concluding that low levels of the hormone melatonin may play a role in developing type 2 diabetes, USA Today reports. They found that women with low levels of melatonin at night had twice the risk of developing type 2 diabetes as those with high levels.
America’s seen a skyrocketing rate of diabetes in recent years. Almost 26 million children ...
continue reading...
A newly approved diabetes drug from Johnson & Johnson may have the potential to be very profitable, given skyrocketing diabetes rates in the Unites States. But a story on the blog Seeking Alpha cautions investors against being too optimistic, given the disappointing results of other diabetes drugs that have gone on the market.
The story mentions GlaxoSmithKline’s Avandia, which has been linked to increased fatalities from heart disease, and is now ...
continue reading...
The U.S. Food and Drug Administration is examining unpublished findings by a group of academic researchers, which suggest a potential link between newer diabetes drugs and pancreatic cancer.
Among the drugs being investigated are Merck’s Januvia and Bristol-Myers Squibb’s Byetta, Bloomberg reports.
Researchers called for an investigation after publishing an analysis of insurance records in the medical journal JAMA Internal Medicine. That analysis concluded that diabetics hospitalized with pancreatitis were twice as ...
continue reading...
A press release from Dr. Sidney Wolfe, director of the Health Research Group for the organization Public Citizen, praises a study published in the journal Diabetes that links a class of diabetes drugs including Byetta and Januvia with pancreatic cancer risk.
Researchers at the University of California, Los Angeles, and the University of Florida, conducted the study. They found increased precancerous changes such as dysplasia in the pancreases of diabetic patients ...
continue reading...
A new study by researchers at the University of California, Los Angeles, adds to growing evidence that a class of diabetes drugs including Merck’s Januvia and Bristol-Myers Squibb’s Byetta carries a risk of pancreatic cancer.
A Bloomberg story says the researchers noted “marked” cell proliferation and damage — with a potential for evolution into cancer — in people with Type 2 diabetes who were taking that type of drug, called incretin ...
continue reading...
